Investors

Shares Research Reports Ad-hoc & Press Presentations Annual general meeting Financial calendar & newsletter

A young success story open to anyone

Just five years after its founding, Cantourage has quickly established itself as a market leader in the European medical cannabis sector, consistently achieving substantial revenue growth year after year. By leveraging its asset-light strategy and cost efficiency, Cantourage achieved break-even in 2023

In preparation for cannabis legalisation in Germany, Cantourage went public in Autumn of 2022 to enable small and institutional investors to be part of a global growth industry. The company is listed on the Frankfurt Stock Exchange under the ticker “HIGH”.

In preparation for cannabis legalisation in Germany, Cantourage went public in Autumn of 2022 to enable small and institutional investors to be part of a global growth industry. The company is listed on the Frankfurt Stock Exchange under the ticker “HIGH”.

So, what does Cantourage do?

Cantourage sources cannabis from around the world, imports it to its European manufacturing hubs to produce pharmaceutical cannabis medicines, and distributes them throughout Europe's fastest growing medical cannabis markets.

Cantourage helps cultivators access Europe’s rapidly expanding medical cannabis markets. So far, Cantourage has signed over 60 long-term contracts with cannabis growers from 18 countries.

Cantourage implemented a revenue-sharing model which allows Cantourage to avoid investing in costly cultivation facilities and long-term purchase commitments, thereby minimising the company's working capital risk.

Cantourage implemented a revenue-sharing model which allows Cantourage to avoid investing in costly cultivation facilities and long-term purchase commitments, thereby minimising the company's working capital risk.

Based at the heart of Europe's cannabis progress

Upon arrival in Germany, Cantourage handles all necessary processes to transform imported cannabis raw material into prescription medicines. For cannabis flowers, these steps include trimming, microbiological load reduction, packaging and labelling, testing, market release, warehousing, and fulfilment. All these processes are carried out at Cantourage’s production facility in Southern Germany, along with its associated laboratories and service providers.

Upon arrival in Germany, Cantourage handles all necessary processes to transform imported cannabis raw material into prescription medicines.

For cannabis flowers, these steps include trimming, microbiological load reduction, packaging and labelling, testing, market release, warehousing, and fulfilment. All these processes are carried out at Cantourage’s production facility in Southern Germany, along with its associated laboratories and service providers.

Since May of 2024, Cantourage has an additional production partner in Portugal to further stabilise the supply chain and security of supply for all of Europe.

Supplying markets as they open

Once manufactured, the products are shipped to pharmacies throughout Cantourage’s home market Germany, as well as, to the UK via its subsidiary Cantourage UK. Additionally, Cantourage distributes products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.

Once manufactured, the products are shipped to pharmacies throughout Cantourage’s home market Germany, as well as, to the UK via its subsidiary Cantourage UK.

Additionally, Cantourage distributes products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.

Spearheading all product categories

In the cannabis flower market, Cantourage is proud to offer the most diversified product portfolio in Europe, with its growers supplying a wide range of different cultivars from value products to craft cannabis – allowing Cantourage to quickly cater to changing patients’ needs and market demands. Since German cannabis legalisation, Cantourage has been witnessing a massive influx in medical cannabis demand, with revenue in April 2024 growing by around 160% compared to the same month of the previous year.

Besides cannabis flowers, Cantourage is also well positioned in other market segments such as extracts and active ingredients. In the German Dronabinol (= pure THC) market, Cantourage has asserted itself amidst experienced big pharma competition and today is one of the market leaders in Europe.

Easing patient access

In both Germany (“Telecan”) and the UK (“Cantourage Clinic”), Cantourage operates its own (telehealth) medical platform to make it easier for people to access medicinal cannabis. Patients can openly discuss cannabis treatment with a doctor - without fear of stigmatisation.
‍
The process is very simple: after registering online, including completing a questionnaire, patients can make an initial appointment and receive their cannabis prescription, which is then sent to a pharmacy of the patient’s choice. In Germany, in addition to an online consultation, it is also possible for patients to visit the expert doctors at their practice locations.

Basic information

ISIN

DE000A3DSV01

LEI

3912003NCTLO6YHA9V48

Ticker Symbol

HIGH

Segment

Scale

Market

Open Market

Class of shares

Bearer shares

Trading venues

XETRA, Frankfurt (Scale), Open Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

Designated Sponsor

Hauck Aufhäuser /mwb fairtrade Wertpapierhandelsbank, both Frankfurt am Main

Specialist

WOLFGANG STEUBING AG

Share capital in EUR

12,467,479.00

Financial year

1 January to 31 December

Number of shares

12,467,479

First trading day

11/11/2022

Securities identification number

A3DSV0

Research

Datum

11.50

Reports

Cantourage Group SE – unauditierter Halbjahresabschluss 2024

Language: German

Cantourage Group SE: Income Statements 2020-2023

Language: English

Cantourage Group SE - Balance Sheets 2020-2023

Language: English

Ad-hoc

December 5, 2024

Ad-hoc: Cantourage Group SE erhöht Jahresprognose für 2024 aufgrund der Beschleunigung der positiven Geschäftsentwicklung zum Jahresende

October 9, 2024

Ad-hoc: Medizinisches Cannabis boomt: Cantourage Group SE verzeichnet Rekordquartal in Q3 2024

May 15, 2024

Ad-hoc: Cantourage Group SE records strong growth in 2024 since the partial legalisation of cannabis came into force

Press releases

December 19, 2024

Cantourage Group SE exports medical craft cannabis for the first time to the growth market of Poland; cooperation with the wholesaler PharmaVitae to be expanded in 2025

December 12, 2024

Cantourage Group SE verzeichnet starke Geschäftsentwicklung im November und erhöht Jahresprognose für 2024

November 20, 2024

New Sales Record: Cantourage Group SE Reports EUR 5.5 Million in Revenue for October 2024, Reaffirming Full-Year Growth Targets

Presentations

Company presentation (July 2024)

Company Overview

Whitepaper on Cannabis for Recreational Use in Germany

we love cannabis

Annual General Meeting

Here you will find detailed information and documents on the Annual General Meeting of Cantourage Group SE, which will take place on Wednesday, 26 June 2024, at 1:00 p.m. on the premises of palisa.de GmbH (top floor) at Palisadenstr. 48, 10243 Berlin.

Investors

A young success story open to anyone

So, what does Cantourage do?

Based at the heart of Europe's cannabis progress

Supplying markets as they open

Spearheading all product categories

Easing patient access

Shares

Stock chart

PRICE – HIGH.F -

Basic information

DE000A3DSV01

3912003NCTLO6YHA9V48

HIGH

Scale

Open Market

Bearer shares

XETRA, Frankfurt (Scale), Open Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

Hauck Aufhäuser /mwb fairtrade Wertpapierhandelsbank, both Frankfurt am Main

WOLFGANG STEUBING AG

12,467,479.00

1 January to 31 December

12,467,479

11/11/2022

A3DSV0

Research

5/12/2024

Montega

Tim Kruse

Buy

11.50

16/10/2024

Montega

Tim Kruse

Buy

11.00

6/12/2024

NuWays

Christian Sandherr

Buy

11.50

Reports

Cantourage Group SE – unauditierter Halbjahresabschluss 2024

Cantourage Group SE: Income Statements 2020-2023

Cantourage Group SE - Balance Sheets 2020-2023

Ad-hoc

Ad-hoc: Cantourage Group SE erhöht Jahresprognose für 2024 aufgrund der Beschleunigung der positiven Geschäftsentwicklung zum Jahresende

Ad-hoc: Medizinisches Cannabis boomt: Cantourage Group SE verzeichnet Rekordquartal in Q3 2024

Ad-hoc: Cantourage Group SE records strong growth in 2024 since the partial legalisation of cannabis came into force

Press releases

Cantourage Group SE exports medical craft cannabis for the first time to the growth market of Poland; cooperation with the wholesaler PharmaVitae to be expanded in 2025

Cantourage Group SE verzeichnet starke Geschäftsentwicklung im November und erhöht Jahresprognose für 2024

New Sales Record: Cantourage Group SE Reports EUR 5.5 Million in Revenue for October 2024, Reaffirming Full-Year Growth Targets

Presentations

Company presentation (July 2024)

Company Overview

Whitepaper on Cannabis for Recreational Use in Germany

Annual General Meeting

Voting summary

Präsentation zur Hauptversammlung am 26.06.2024

Report of the Supervisory Board

Audit report annual financial statements as at 31/12/2022

Amendment of instructions to the company's proxies

Power of attorney revocation form

Authorisation form

Directions and parking facilities

Invitation to the Annual General Meeting

Presentation for the Annual General Meeting on 28/06/2023

Appropriation of earnings 2023

Information according to §125 AktG

Voting summary

Invitation to the Annual General Meeting

Directions and parking facilities

Authorisation form

Power of attorney revocation form

Amendment of instructions to the company's proxies

Audit report annual financial statements as at 31/12/2023

Report of the Supervisory Board

Financial calendar & newsletter

Annual general meeting, Berlin

Thank you for the message!

We're rolling up our sleeves to craft a response that is as smooth as our finest strains.

Stay tuned!